IMP Accountability refers to the process of tracking and documenting the lifecycle of an Investigational Medicinal Product (IMP) throughout a clinical trial. This includes maintaining accurate records of the receipt, storage, dispensing, administration, return, and disposal of the IMP at all stages of the study.
The purpose of IMP Accountability is to ensure regulatory compliance, patient safety, and data integrity in clinical research. It helps investigators and sponsors demonstrate that the IMP was handled correctly and administered only to eligible study participants in accordance with the approved protocol.
IMP Accountability is crucial for maintaining the integrity and validity of clinical trial results. It ensures that the investigational product is used as intended, minimizing the risk of errors that could compromise patient safety or study outcomes. Proper accountability also helps detect and prevent potential fraud or misconduct in clinical research.
Furthermore, IMP Accountability is essential for regulatory compliance and auditing purposes. It provides a clear trail of evidence that can be reviewed by regulatory authorities to verify adherence to Good Clinical Practice (GCP) guidelines. This documentation is vital for the approval process of new drugs and therapies, demonstrating the reliability of the clinical trial data.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant